



**Source:** Syncromune

June 16, 2025 08:30 ET

# Syncromune® Appoints Industry Veteran Kerri-Ann Millar as Chief Financial Officer to Advance Corporate Growth Initiatives and Clinical Development Program

## Millar to Lead Financial Strategy as Syncromune Scales Development of the SYNC-T® Novel Immunotherapy Platform for Solid Tumor Cancers

FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, June 16, 2025 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company pioneering SYNC-T, an *in situ* personalized combination immunotherapy platform for solid tumor cancers, today announced the appointment of Kerri-Ann Millar, CPA, as Chief Financial Officer.

Ms. Millar brings over two decades of financial leadership experience in the life sciences industry, including a successful track record guiding both public and emerging biotechs through critical phases of growth, IPOs, financing, and commercialization. Her appointment comes at a pivotal time for Syncromune as the company advances its lead program, SYNC-T Therapy SV-102 for metastatic castration-resistant prostate cancer, into its [Phase 2a LEGION-100 trial](#). Ms. Millar will focus on supporting clinical development, strengthening financial operations, and executing the company's long-term financial strategy.

"Kerri-Ann brings a rare combination of financial rigor, operational leadership, and deep industry expertise that makes her an exceptional fit for Syncromune," said Eamonn Hobbs, Co-Founder, President and CEO of Syncromune. "Her track record leading companies through critical phases of fundraising, strategic transactions, and organizational scale-up through commercialization will be instrumental as we continue advancing our pipeline and expanding operations and we're thrilled to welcome her to the leadership team."

Prior to joining Syncromune, Ms. Millar served as Chief Financial Officer at Cue Biopharma, a publicly traded immunotherapy company, where she was responsible for the finance, investor relations, HR, and IT functions. During her tenure, she led multiple financing transactions totaling

more than \$300 million, including the company's initial public offering. She previously held senior financial leadership roles at Flexion Therapeutics, where she supported the company through IPO, clinical development, and commercial launch, and at Curis, Inc., where she led Sarbanes-Oxley compliance and SEC reporting. Ms. Millar began her career in public accounting at PricewaterhouseCoopers.

"Syncromune is pursuing a bold vision to transform how metastatic cancers are treated through a truly novel immunotherapy platform," said Ms. Millar. "I'm excited to join a team that is innovative, mission-driven, and deeply committed to developing solutions to help patients with advanced cancers. I look forward to supporting the company's continued growth and executing a financial strategy that enables us to deliver our therapy to patients in need."

Ms. Millar earned her B.S. in Accounting from Boston University and is a Certified Public Accountant in the Commonwealth of Massachusetts.

For more information about Syncromune, please visit [www.syncromune.com](http://www.syncromune.com).

### **About Syncromune® and SYNC-T® Therapy**

Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, a potentially first-in-class platform immunotherapy designed to address major unmet needs and treatment challenges of incurable metastatic solid tumor cancers. SYNC-T is an *in situ* personalized cancer therapy engineered to synchronize the location of three components critical to T cell activation and an anti-tumor immune response: patient-specific tumor antigens, immune cells, and our multi-target biologic drug. SYNC-T features a novel proprietary device delivery system that is optimized for combination drug/device immunotherapy. First, the system lyses a portion of a target tumor to rupture tumor cells and release patient-specific tumor antigens into the tumor microenvironment (TME) that help to activate the immune system. Next, the delivery system facilitates the infusion of our proprietary multi-target biologic drug directly into the lysed area of the tumor. This approach of location synchronization is designed to unite the three critical components together in the TME and lymphatics where the immune system optimally functions. The combination therapy targets numerous mechanisms of cancer, promoting *in situ* immune activation while also battling immune suppression and minimizing systemic drug exposure. The goal is to educate the immune system and activate T cells that can recognize and attack cancer throughout the body and defend with immune memory. Our lead candidate, SYNC-T Therapy SV-102 for metastatic castration-resistant prostate cancer (mCRPC), is being evaluated in the LEGION-100 U.S., multicenter, Phase 2a trial. For more information, please visit [www.legion100trial.com](http://www.legion100trial.com).

*This press release includes forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained in this press release or expressed orally in connection herewith that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, forward-looking statements can be identified by phrases such as "plans," "intends," "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Accordingly, you should not place undue reliance on our forward-looking statements. The forward-looking statements contained in this press release or expressed orally in connection herewith are made only as of the date of this press release and we undertake no obligation to update the forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law. None of Syncromune, Inc., its affiliates or their respective directors, officers, employees or agents gives any representation or warranty, express or implied, as to: (i) the achievement or reasonableness of future projections, management targets, estimates or prospects contained in this press release; or (ii) the accuracy or completeness of any information contained in this press release, any other written information or oral information provided in connection herewith or any data that any of them generates. This press release was prepared by us for informational purposes only and does not constitute an offer, or solicitation of an offer, to sell any securities at any time. None of Syncromune's securities have been registered under the Securities Act of 1933, as amended, or any state securities law. Such securities have not been approved or disapproved by the Securities and Exchange Commission or by any state securities regulatory authority, nor has the Securities and Exchange Commission or any such state authority passed on*

*the accuracy or adequacy of this press release. Any representation to the contrary is a criminal offense. Some of the information contained in this press release may be derived from information provided by industry sources. We believe that such information is accurate and that the sources from which it has been obtained are reliable; however, we cannot guarantee the accuracy of such information and have not independently verified such information.*

**Corporate Contact**

Danielle Hobbs  
EVP, Corporate Communications  
Syncromune, Inc.  
**media@syncromune.com**

**Media Contact**

Michael Tattory  
LifeSci Communications  
**mtattory@lifescicomms.com**